Document:

Exhibit 4.8

 

[Form of
Warrant Certificate]

 

[FACE]

 

Number

 

Warrants

 

THIS
WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO

THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR

IN THE WARRANT AGREEMENT DESCRIBED BELOW

 

MEMIC
INNOVATIVE SURGERY LTD.

Organized
Under the Laws of the State of Israel

 

CUSIP
[●]

 

Warrant
Certificate

 

This
Warrant Certificate certifies that                       ,
or registered assigns, is the registered holder of                       
warrant(s) evidenced hereby (the “Warrants” and each, a “Warrant”) to purchase
ordinary shares, no par value (“Ordinary Shares”), of Memic Innovative Surgery Ltd., a company organized under
the laws of the State of Israel (the “Company”). Each whole Warrant entitles the holder, upon exercise
during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and non-assessable
Ordinary Shares as set forth below, at the exercise price (the “Exercise Price”) as determined pursuant to
the Warrant Agreement, payable in lawful money (or through “cashless exercise” as provided for in the Warrant
Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the Exercise Price at the office
or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement. Defined
terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

 

Each
whole Warrant is initially exercisable for one fully paid and non-assessable Ordinary Share. No fractional shares will be issued
upon exercise of any Warrant. If, upon the exercise of a Warrant, a holder would be entitled to receive a fractional interest in an Ordinary
Share, the Company will, upon exercise, round down to the nearest whole number of the number of Ordinary Shares to be issued to the holder.
The number of Ordinary Shares issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set
forth in the Warrant Agreement.

 

The
initial Exercise Price per Ordinary Share for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment
upon the occurrence of certain events set forth in the Warrant Agreement.

 

Subject
to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent
not exercised by the end of such Exercise Period, such Warrants shall become void. 

 

The
Warrants may be redeemed, subject to certain conditions, as set forth in the Warrant Agreement.

 

Reference
is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall
for all purposes have the same effect as though fully set forth at this place.

 

This
Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

 

This
Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York, without regard
to conflicts of laws principles thereof.

 

     

     

    

 

	MEMIC INNOVATIVE
    SURGERY LTD.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 
	CONTINENTAL STOCK
    TRANSFER	 
	& TRUST COMPANY,
    as Warrant Agent	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

    2

     

    

 

[Form of
Warrant Certificate]

 

[Reverse]

 

The
Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive 
                     Ordinary
Shares and are issued or to be issued pursuant to the Warrant Agreement, dated December 17, 2020, by and between MedTech Acquisition
Corporation and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”),
as modified by an Assignment, Assumption and Amendment Agreement dated as of                   ,
2021 (collectively and as amended from time to time, the “Warrant Agreement”), by and among MedTech Acquisition
Corporation, the Company and the Warrant Agent, which Warrant Agreement is hereby incorporated by reference in and made a part of this
instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder
of the Warrant Agent, the Company and the holders (the words “holders” or “holder”
meaning the Registered Holders or Registered Holder) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder
hereof upon written request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the
meanings given to them in the Warrant Agreement.

 

Warrants
may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by
this Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth
hereon properly completed and executed, together with payment of the Exercise Price as specified in the Warrant Agreement (or through
“cashless exercise” as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent.
In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number
of Warrants evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing
the number of Warrants not exercised.

 

Notwithstanding
anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a
registration statement covering the Ordinary Shares to be issued upon exercise is effective under the Securities Act and (ii) a
prospectus thereunder relating to the Ordinary Shares is current, except through “cashless exercise” as provided for in the
Warrant Agreement.

 

The
Warrant Agreement provides that upon the occurrence of certain events the number of Ordinary Shares issuable upon exercise of the Warrants
set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof
would be entitled to receive a fractional interest in an Ordinary Share, the Company shall, upon exercise, round down to the nearest
whole number of Ordinary Shares to be issued to the holder of the Warrant.

 

Warrant
Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person
or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided
in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like
tenor evidencing in the aggregate a like number of Warrants.

 

Upon
due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate
or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in
exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax
or other governmental charge imposed in connection therewith.

 

The
Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant
Certificate (notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise
hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent
shall be affected by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof
to any rights of a stockholder of the Company.

 

    3

     

    

 

Election
to Purchase

 

(To
Be Executed Upon Exercise of Warrant)

 

The
undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive           
Ordinary Shares and herewith tenders payment for such Ordinary Shares to the order of Memic Innovative Surgery Ltd. (the “Company”)
in the amount of $           in accordance with the terms hereof. The undersigned requests
that a certificate for such Ordinary Shares be registered in the name of       , whose address is           
and that such Ordinary Shares be delivered to                  
whose address is                .  If said number of
Ordinary Shares is less than all of the Ordinary Shares purchasable hereunder, the undersigned requests that a new Warrant Certificate
representing the remaining balance of such Ordinary Shares be registered in the name of                ,
whose address is                    and that such Warrant
Certificate be delivered to                , whose address
is                .

 

In
the event that the Warrant has been called for redemption by the Company pursuant to Section 6.1 of the Warrant
Agreement and the Company has required cashless exercise pursuant to Section 6.4 of the Warrant Agreement, the
number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(b) and Section 6.4 of
the Warrant Agreement.

 

In
the event that the Warrant is a Private Placement Warrant or a Working Capital Warrant that is to be exercised on a “cashless”
basis pursuant to subsection 3.3.1(c) of the Warrant Agreement, the number of Ordinary Shares that this Warrant is exercisable
for shall be determined in accordance with subsection 3.3.1(c) of the Warrant Agreement.

 

In
the event that the Warrant is to be exercised on a “cashless” basis pursuant to Section 7.4 of the
Warrant Agreement, the number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with Section 7.4 of
the Warrant Agreement.

 

In
the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number
of Ordinary Shares that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement
which allows for such cashless exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably
elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement,
to receive Ordinary Shares. If said number of shares is less than all of the Ordinary Shares purchasable hereunder (after giving
effect to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such
Ordinary Shares be registered in the name of                ,
whose address is                    and that such Warrant
Certificate be delivered to                , whose address
is                .

 

[Signature
Page Follows]

 

    4

     

    

 

	Date:                 
    ,     21	 	 
	 	 	(Signature)
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	(Address)
	 	 	 
	 	 	 
	 	 	(Tax Identification Number)
	 	 	 
	Signature Guaranteed:	 	 
	 	 	 
	 	 	 

 

THE
SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT
UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED (OR ANY SUCCESSOR RULE)).

 

    5Exhibit 4.10

 

THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT ARE BEING ACQUIRED SOLELY FOR INVESTMENT AND HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE OR COMPARABLE SECURITIES
LAW OF A NON-U.S. JURISDICTION AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT COVERING THIS WARRANT AND/OR SUCH SECURITIES, OR THE COMPANY RECEIVES AN OPINION OF
COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL STATING THAT SUCH SALE, OFFER, PLEDGE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT
FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT AND OF ANY OTHER APPLICABLE STATE OR COMPARABLE SECURITIES LAW
OF A NON-U.S. JURISDICTION. HOLDERS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE
PERIOD OF TIME.

 

WARRANT
TO PURCHASE SERIES C-1 PREFERRED SHARES of Me-mic Innovative Surgery Ltd. 

 

warrant
number ____

 

This
Warrant (this “Warrant”) is issued
on [February __], 2018 (the “Warrant Issue Date”) to ____________ (the “Holder”) by Me-mic Innovative
Surgery Ltd., a company incorporated under the laws of the State of Israel (the “Company”), pursuant to the terms
of the Series C Preferred Share Purchase Agreement, dated as of [February __], 2018, by and among the Company, the Holder and the other
parties thereto (the “SPA”). This Warrant is one of a series of Warrants being issued in connection with the SPA.
Unless otherwise defined herein, all capitalized terms used in this Warrant shall have the meanings ascribed to them in the SPA.

 

		1.	Purchase
                                            Shares. Subject to the terms and conditions hereinafter set forth, the Holder is entitled
                                            to purchase from the Company up to [____] fully paid and non-assessable Preferred C-1 Shares
                                            of the Company, each with a nominal value of NIS 0.01 (the “Shares”).
                                            The number of the Shares issuable pursuant to this Section 1 may be adjusted from time
                                            to time pursuant to the terms hereof. In addition, in the event that the Holder becomes a
                                            Defaulting Investor (as defined in the SPA) then, upon written notice from the Company to
                                            the Holder, the number of Shares subject to this Warrant shall be reduced by fifty percent
                                            (50%).

 

		2.	Exercise
                                            Price. The purchase price for each Share purchasable under this Warrant, as may be adjusted
                                            from time to time pursuant to the terms hereof shall be US$0.8918 (the “Exercise
                                            Price Per Share”). The aggregate purchase price for all of the Shares purchasable
                                            hereunder is US$[________] (the “Exercise Price”).

 

     

     

    

 

		3.	Exercise
                                            Period. This Warrant shall be exercisable, at any time, as of the Warrant Issue Date
                                            until the earlier to occur of: (i) the expiration of 10 years from the date of the Initial
                                            Closing; (ii) the consummation of an sale of the Company’s Ordinary Shares to the public
                                            in a bona fide, underwritten, public offering pursuant to a registration statement under
                                            the Act of 1933, the Israeli Securities Law or similar securities laws of another jurisdiction
                                            (an “IPO”); or (iii) a Deemed Liquidation Event (as defined in the Amended
                                            Articles) (the “Exercise Period”). This Warrant shall, at the end of the
                                            Exercise Period, no longer be exercisable and become null and void. In any of the events
                                            described in (ii) and (iii) above, the Company shall provide the Holder with prior written
                                            notice thereof at least 5 days prior to the occurrence of such event.

 

		4.	Method
                                            of Exercise. At any time during the Exercise Period the Holder may exercise this Warrant,
                                            in whole or in part, on one or more occasions. Such exercise shall be effected by the surrender
                                            of this Warrant, together with a duly executed copy of the form of Notice of Exercise attached
                                            hereto, to the chief executive officer of the Company at its principal offices and the payment
                                            to the Company of an amount equal to the aggregate of the Exercise Price for all of the Shares
                                            being purchased, in immediately available cash funds in US dollars. Notice of exercise of
                                            this Warrant (i) in connection with an IPO may be made conditional upon closing of such public
                                            offering, and (ii) in connection with a Deemed Liquidation Event may be made conditional
                                            upon closing of such event.

 

		5.	Exercise
                                            on Net Issuance Basis. Unless the Holder elects to exercise this Warrant pursuant to
                                            Section 4 above, this Warrant will be deemed exercised, without the payment by the Holder
                                            of any additional consideration, upon the earlier of the consummation of (i) the consummation
                                            of an IPO; (ii) a Deemed Liquidation Event, (iii) the expiration of 10 years from the date
                                            of the Initial Closing, or (iv) the written request of Holder to exercise this Warrant in
                                            whole or in part on a net issuance basis, into the number of Shares that to be calculated
                                            pursuant to the following formula:

 

X
= Y (A-B)

A

 

Where:

 

X
= the number of Shares to be issued to the Holder pursuant to this Section 5.

 

Y
= the number of Shares purchasable under this Warrant (as adjusted to the date of such calculation,
but excluding those Shares already issued under this Warrant).

 

A
= the Fair Market Value (as defined below) of one Share as at the time the exercise is deemed
made pursuant to this Section 5.

 

B
= the Exercise Price.

 

For
purposes of the above calculation, “Fair Market Value” of one Share shall be (a) ) in the event of an exercise
occurring in connection with the consummation of the IPO, the per share offering price to the public of one share into which a Preferred
C-1 Share has been or will be converted; (b) in the event of an exercise occurring in connection with the consummation of a Deemed Liquidation
Event, the per share consideration payable to holders of Preferred C-1 Shares for each such share in connection with such transaction
or (c) as determined by the Board of Directors of the Company if exercised in another circumstance (not in connection with a IPO or a
Deemed Liquidation Event).

 

    2

     

    

 

		6.	Issuance
                                            of Shares on Exercise. The Company agrees that following an exercise as provided in Sections
                                            4 and 5 above, the Shares so purchased shall be issued and the Holder shall be deemed the
                                            record owner of such Shares as of the close of business on the date on which the last of
                                            the actions required to exercise the Warrant as provided in Sections 4 and 5 above has been
                                            completed (the “Warrant Exercise Date”).

 

		7.	Certificates
                                            for Shares: New Warrant. Upon the exercise of the purchase rights evidenced by this Warrant,
                                            the Company shall issue a share certificate, for the number of Shares so purchased as soon
                                            as practicable thereafter. Prior to the expiration of the Exercise Period, following any
                                            partial exercise of the Warrant hereunder, the Company shall issue to the Holder a new Warrant
                                            representing the right of the Holder to purchase the remaining Shares under this Warrant
                                            not yet purchased.

 

		8.	Authorization
                                            and Reservation of Shares. During the Exercise Period, the Company will at all times
                                            have authorized, and hold in reserve for issuance upon exercise of this Warrant, a sufficient
                                            number of Preferred C-1 Shares to provide for the exercise of the rights represented by this
                                            Warrant. The Company represents and warrants that the Shares, when issued, sold and delivered
                                            pursuant to the exercise of this Warrant for the consideration expressed herein, will be
                                            duly and validly issued, fully paid and non assessable and free and clear of any preemptive
                                            rights. The Company shall pay all charges that may be payable in connection with the preparation
                                            and delivery of share certificates pursuant to Section 6 in the name of the Holder. The Company
                                            further agrees that it will not, by amendment of its Amended Articles or through reorganization,
                                            consolidation, merger, dissolution or sale of assets, or by any other voluntary act, avoid
                                            or seek to avoid the observance or performance of any of the covenants, stipulations or conditions
                                            to be observed or performed hereunder by the Company.

 

		9.	Adjustment
                                            of Exercise Price and Number of Shares The number of and kind of securities purchasable
                                            upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from
                                            time to time as follows:

 

(i) Subdivisions
and Combinations. If the Company shall at any time prior to the expiration of the Exercise Period subdivide its Preferred C-1 Shares,
by share split or otherwise, or combine its Preferred C-1 Shares, then the number of Shares issuable on the exercise of this Warrant
shall forthwith, be proportionately increased in the case of a share split, subdivision or share dividend, or proportionately decreased
in the case of a combination or similar action. Appropriate adjustments shall also be made to the Exercise Price payable, but the Exercise
Price payable for the total number of Shares purchasable under this Warrant, as adjusted, shall remain the same as it was prior to the
aforesaid adjustments and further provided that the Exercise Price cannot be reduced lower than NIS 0.01. Any adjustment under this Section 9(i)
shall become effective at the close of business on the date the subdivision or combination becomes effective.

 

    3

     

    

 

(ii) Adjustment
for Dividends or Distributions of Securities or Property. In the event the Company shall, prior to the end of the Exercise Period,
make or issue, or shall fix a record date for the determination of eligible holders entitled to receive, a dividend or other distribution
payable in securities of the Company,, then this Warrant shall represent the right to acquire, in addition to the number of Shares indicated
above, and without payment of any additional consideration therefor, the securities of the Company to which such Holder would have been
entitled upon such date if such Holder had exercised this Warrant in full on the date hereof and had thereafter, during the period from
the date hereof to and including the date of such exercise, retained such Shares and all other additional securities of the Company during
such period giving effect to all adjustments called for by this Section 9.

 

(iii) Reclassification,
Reorganization, Merger and Consolidation. In case of any reclassification, capital reorganization, or change in the share capital
of the Company (other than as a result of the events provided for in Section 9(i) and (ii) above) or any merger or consolidation
of the Company with or into another corporation that is not a Deemed Liquidation Event, then as a condition of such reclassification,
reorganization, change, merger or consolidation, lawful provision shall be made, and duly executed documents evidencing the same from
the Company or its successor shall be delivered to the Holder, so that the Holder shall have the right at any time prior to the expiration
of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares
or other securities receivable in connection with such reclassification, reorganization, change, merger or consolidation by a holder
of the same number of Shares as were purchasable by the Holder if this Warrant had been exercised immediately prior to such reclassification,
reorganization, change, merger or consolidation. In any such case appropriate provisions shall be made with respect to the rights and
interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares or other securities deliverable
upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price payable hereunder, provided that the aggregate
purchase price shall remain the same.

 

(iv) Notice
of Adjustment. When any adjustment is required to be made in the number or kind of securities purchasable upon exercise of the Warrant,
or in the Exercise Price, the Company shall notify the Holder, in writing, of such event and of the number of Preferred C-1 Shares or
other securities thereafter purchasable upon exercise of this Warrant.

 

(v) Notice
of Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for the purpose
of determining the holders thereof who are entitled to receive any dividend (including a cash dividend) or other distribution, any
right to subscribe for, purchase or otherwise acquire any shares of any class or any other securities or property, or to receive any
other right, the Company shall send to the Holder a notice, which shall be sent simultaneously with the notice sent to other
shareholders of the Company, specifying the date on which any such record is to be taken for the purpose of such dividend,
distribution or right, and the amount and character of such dividend, distribution or right.

 

		10.	Fractional
                                            Shares. No fractional shares shall be issued upon the exercise of this Warrant, and the
                                            number of Warrant Shares issued shall be rounded to the nearest whole number.

 

    4

     

    

 

		11.	Shareholder
                                            Rights. Prior to an exercise under this Warrant, except as set forth in this Warrant,
                                            the Holder shall not, by virtue hereof, be entitled to any rights of a shareholder in the
                                            Company including (without limitation) the right to vote such Shares, receive dividends or
                                            other distributions thereon, exercise preemptive rights or be notified of shareholder meetings.
                                            Without limiting the foregoing or any remedies available to the Holder, the Holder will be
                                            entitled to specific performance of the obligations hereunder

 

		12.	Registration
                                            Rights. All Shares issuable upon exercise of this Warrant shall be “Registrable
                                            Securities,” and the Holder will be deemed for all purposes a “Holder”
                                            and an “Investor” under the terms of the Investors’ Rights Agreement, or
                                            any amending or replacing agreement for all purposes.

 

		13.	Successors
                                            and Assigns. This Warrant may not be assigned or transferred in any way by Company without
                                            the prior written consent of the Holder. The terms and provisions of this Warrant shall inure
                                            to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators
                                            of the Company and the Holder hereof. This Warrant may not be Transferred (as such term is
                                            defined in the Company’s Amended Articles) by the Holder other than to a Permitted
                                            Transferee (as such term is defined in the Company’s Amended Articles) or as otherwise
                                            approved by the Company in writing.

 

		14.	Amendments
                                            and Waivers. This Warrant and all other Warrants issued under the SPA and outstanding
                                            as of the date of any amendment or waiver, may be amended and provisions may be waived only
                                            by written consent of the Company and holders of majority in interests of such Warrants.

 

		15.	Notices,
                                            etc. All notices and other communications required or permitted hereunder shall be in
                                            writing and shall be mailed by first class mail, postage prepaid, sent by facsimile or electronic
                                            mail or otherwise delivered by hand, overnight courier or by messenger addressed:

 

(a) if
to a Holder, at the Holder’s address, facsimile number or electronic mail address as shown in the Company’s records, as may
be updated in accordance with the provisions hereof.

 

(b)
if to the Company, one copy should be sent to Me-mic Innovative Surgery Ltd., at 6 Yoni Netanyahu Street, Or Yehuda 6037604, Israel,
Attn: CEO, or at such other address as the Company shall have furnished to the Holder, with a copy to Tadmor & Co. Yuval Levy &
Co., 132 Begin Road, Azrieli Center Square Tower, 34th Floor, Tel Aviv 6701101, Israel, Attn: Elie Sprung, Adv. Fax: +972-3-6846001,
E-mail: elie@tadmor-levy.com.

 

A
Notice delivered personally shall be deemed received upon its delivery. A Notice sent by facsimile transmission or by electronic mail
shall be deemed received on the business day following the day on which it was sent. A Notice sent by mail shall be deemed received by
a party whose address is in Israel, three (3) days after its delivery to the post office or; if the address of a party is outside of
Israel, within seven (7) days after the notice is delivered to a post office in Israel and sent by air mail.

 

    5

     

    

 

		16.	Delays
                                            or Omissions. Except as expressly provided herein, no delay or omission to exercise any
                                            right, power or remedy accruing to any party to this Warrant upon any breach or default of
                                            any other party under this Warrant shall impair any such right, power or remedy of such non-defaulting
                                            party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
                                            therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver
                                            of any single breach or default be deemed a waiver of any other breach or default theretofore
                                            or thereafter occurring. Any waiver, permit, consent or approval of any kind or character
                                            on the part of any party of any breach or default under this Warrant, or any waiver on the
                                            part of any party of any provisions or conditions of this Warrant, must be in writing and
                                            shall be effective only to the extent specifically set forth in such writing. All remedies,
                                            either under this Warrant or by law or otherwise afforded to any party to this Warrant, shall
                                            be cumulative and not alternative.

 

		17.	Severability.
                                            If any provision of this Warrant becomes or is declared by a court of competent jurisdiction
                                            to be illegal, unenforceable or void, portions of such provision, or such provision in its
                                            entirety, to the extent necessary, shall be severed from this Warrant, and such court will
                                            replace such illegal, void or unenforceable provision of this Warrant with a valid and enforceable
                                            provision that will achieve, to the extent possible, the same economic, business and other
                                            purposes of the illegal, void or unenforceable provision. The balance of this Warrant shall
                                            be enforceable in accordance with its terms.

 

		18.	Counterparts.
                                            This Warrant may be executed in any number of counterparts, each of which shall be enforceable
                                            against the parties that execute such counterparts, and all of which together shall constitute
                                            one instrument.

 

		19.	Titles
                                            and Subtitles. The titles and subtitles used in this Warrant are used for convenience
                                            only and are not to be considered in construing or interpreting this Warrant. All references
                                            in this Warrant to sections, paragraphs and exhibits shall, unless otherwise provided, refer
                                            to sections and paragraphs hereof and exhibits attached hereto.

 

		20.	Electronic
                                            Execution and Delivery. A facsimile, digital or other reproduction of this Warrant may
                                            be executed by one or more parties hereto and delivered by such party by facsimile or any
                                            similar electronic transmission device pursuant to which the signature of or on behalf of
                                            such party can be seen. Such execution and delivery shall be considered valid, binding and
                                            effective for all purposes. At the request of any party hereto, all parties hereto agree
                                            to execute and deliver an original of this Warrant as well as any facsimile, telecopy or
                                            other reproduction hereof.

 

		21.	Lost
                                            Stolen Warrants. Etc. In case this Warrant or any replacement thereof shall be mutilated,
                                            lost, stolen or destroyed, the Company shall issue a new Warrant of like date, tenor, and
                                            denomination and deliver the same in exchange and substitution for and upon surrender and
                                            cancellation of any mutilated Warrant, or in lieu of any Warrant lost, stolen or destroyed,
                                            upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft
                                            or destruction.

 

    6

     

    

 

		22.	Attorneys’
                                            Fees. If any action of law or equity is necessary to enforce or interpret the terms of
                                            this Warrant, the prevailing party shall be entitled to its reasonable attorneys’ fees,
                                            costs and disbursements in addition to any other relief to which it may be entitled.

 

		23.	Governing
                                            Law and Jurisdiction. This Warrant and any controversy arising out of or relating to
                                            this Warrant shall be governed by, and construed in accordance with, the Israeli Law, and
                                            such matters shall be resolved exclusively by the competent courts of Tel Aviv - Jaffa, Israel.

 

[Signature
Page Follows]

 

    7

     

    

 

SIGNATURE
PAGE OF WARRANT NO. ____

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by a duly authorized officer.

 

	ME-MIC INNOVATIVE SURGERY LTD.	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

    8

     

    

 

INVESTOR
SIGNATURE PAGE OF WARRANT NO. ____

 

	Agreed and Accepted:	 
	 	 	 
	[_________________]	 
	 	 
	By:	 	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 
	 	 	 
	Date:	 	 

 

    9

     

    

 

NOTICE
OF EXERCISE

 

		To:	Me-mic
Innovative Surgery Ltd.

 

The
undersigned hereby (check the applicable box):

 

		☐	elects
to purchase ______ Preferred C-1 Shares of the Company (the “Shares”), pursuant to the terms of the attached Warrant.
The aggregate Exercise Price with respect to such purchase in the amount of US$_____________ shall be paid forthwith in immediately available
cash funds

 

		☐	elects
the Net Issue Basis option pursuant to Section 5 of the Warrant, and accordingly requests delivery of a net of ______________ of
such securities, according to the terms of Section 5 of the Warrant.

 

	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:	 
	 	 	 
	 	Address:	 
	 	 	 
	 	Date:	 

 

    10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]